Impact of age-, cancer-, and treatment-driven inflammation on T cell function and immunotherapy. Issue 3 (17th July 2020)

• Record Type: Journal Article
• Authors: Quinn, Kylie M; Kartikasari, Apriliana E R; Cooke, Rachel E; Koldej, Rachel M; Ritchie, David S; Plebanski, Magdalena
• Is Part Of: Journal of leukocyte biology. Volume 108:Issue 3(2020)
• Page Start: 953
• Page End: 965
• Publication Date: 2020-07-17
• Subjects: IL-1 -- IL-6 -- multiple myeloma -- ovarian cancer -- TNF; Leucocytes -- Periodicals; Reticulo-endothelial system -- Periodicals; 571.96
• DOI: 10.1002/JLB.5MR0520-466R
• Languages: English
• ISSNs: 0741-5400

Abstract

Abstract: Many cancers are predominantly diagnosed in older individuals and chronic inflammation has a major impact on the overall health and immune function of older cancer patients. Chronic inflammation is a feature of aging, it can accelerate disease in many cancers and it is often exacerbated during conventional treatments for cancer. This review will provide an overview of the factors that lead to increased inflammation in older individuals and/or individuals with cancer, as well as those that result from conventional treatments for cancer, using ovarian cancer (OC) and multiple myeloma (MM) as key examples. We will also consider the impact of chronic inflammation on immune function, with a particular focus on T cells as they are key targets for novel cancer immunotherapies. Overall, this review aims to highlight specific pathways for potential interventions that may be able to mitigate the impact of chronic inflammation in older cancer patients. Graphical Abstract: Age-, disease- and treatment-driven inflammation can all limit T cell function in older cancer patients and this should be a critical consideration for T cell-targeted immunotherapies.